Tazemetostat, the first oral enhancer of zeste homolog 2 (EZH2) inhibitor, has been approved for EZH2 mutation-positive follicular lymphoma and epithelioid sarcoma [29, 30]. Here, EZH2 is linked to epithelioid sarcoma.